Alpha-2 Antiplasmin Market by Forms 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Alpha-2 Antiplasmin Market
Alpha-2 Antiplasmin Market Analysis: by Forms (Plasminogen Binding and Non-Plasminogen Binding); End-users (Clinics, Diagnostic Labs, Hospitals, Private Labs); and Geography – Forecast 2016-2021
Report Code : HCR 0103
Published: 11 January, 2016   No. of pages: 142

  • Report Description
  • Table of Contents
  • Customization Options
A type of glycoprotein, Alpha-2 Antiplasmin, is synthesized by kidneys, liver and various different tissues of the body. Alpha-2 Antiplasmin is the type of protein which is responsible for degradation of fibrin clots. It is also liable for inhibition of fibrinolysis. Lack of Alpha-2 Antiplasmin protein causes bleeding disorder owing to the increase in fibrinolysis. Alpha-2 Antiplasmin is used in various types of diagnostic technologies such as Immunohistochemistry – Frozen (IHC-F) and immunohistochemistry – Paraffin (IHC-P). Other diagnostic technologies include flow cytometry and enzyme linked immuno-sorbent assay (ELISA). Alpha-2 Antiplasmin is largely used in hospital and diagnostic labs. The global Alpha-2 Antiplasmin market is expected to witness high growth in terms of value over the forecast period.

Increasing healthcare industry is expected to be a major driving factor for the growth of global Alpha-2 Antiplasmin market over the forecast period. Growing number of metabolic syndrome and various other cardiovascular diseases has led to increase in the demand for Alpha-2 Antiplasmin, thus driving the global Alpha-2 Antiplasmin market in the near future. In addition to this, the advancement in coagulation testing practices is anticipated to drive the global Alpha-2 Antiplasmin market over the forecast period. Increasing consumption of computerized instrumentation is also projected to augment the global Alpha-2 Antiplasmin market over the forecast period. Stringent regulations are also expected to constrain the growth of Alpha-2 Antiplasmin market over the forecast period.

However, need for highly sophisticated instruments are anticipated to restrain the global Alpha-2 Antiplasmin market in the near future.

The global Alpha-2 Antiplasmin market is classified on the basis of Forms as plasminogen binding and non-plasminogen binding.

The global Alpha-2 Antiplasmin market is further bifurcated on the basis of end-users into clinics, diagnostic labs, hospitals and private labs.

Lastly, the global Alpha-2 Antiplasmin market is bifurcated by regions as North America, Rest of the World, Asia Pacific and Europe. Asia Pacific is expected to dominate the global Alpha-2 Antiplasmin market throughout the forecast period. This is mainly attributed to rapid growth in healthcare industry in India and China. North America and Europe, being mature markets are expected to witness sluggish growth over the forecast period. Middle East and Africa is also expected witness high growth in the globalAlpha-2 Antiplasmin market over the forecast period. Japan is anticipated to witness stagnant growth in the global Alpha-2 Antiplasmin market in the near future.

Alpha-2 Antiplasmin Market

A few of the key players identified in the global Alpha-2 Antiplasmin market include:
  • Abbott Laboratories (U.S.)
  • Becton, Dickinson and Company (U.S.)
  • Bio/Data Corporation (U.S.)
  • Axis-Shield Diagnostics Ltd. (U.K.)
  • Helena Company Inc. (U.S.)
  • Sysmex Corporation (Japan) among others.
1. Alpha-2 Antiplasmin– Market Overview
2. Executive Summary
3. Alpha-2 Antiplasmin– Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Patent Analysis
      3.2.4. Top 5 Financials Analysis
4. Alpha-2 Antiplasmin– Market Forces
   4.1. Market Drivers
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Alpha-2 Antiplasmin Industry
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Alpha-2 Antiplasmin Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Suppliers/Distributors Analysis
6. Alpha-2 Antiplasmin Market – By Forms:
   6.1. Introduction
   6.2. Plasminogen Binding  and
   6.3. Non-Plasminogen Binding
7. Alpha-2 Antiplasmin Market – By End-users:
   7.1. Clinics,
   7.2.  Diagnostic Labs,
   7.3.  Hospitals and
   7.4.  Private Labs
8. Alpha-2 Antiplasmin Market- By Geography:
   8.1. Introduction
   8.2. North America
      8.2.1. U.S.
      8.2.2. Canada
      8.2.3. Mexico
      8.2.4. Rest of North America
   8.3. Europe
      8.3.1. France
      8.3.2. Germany
      8.3.3. Italy
      8.3.4. Spain
      8.3.5. U.K
      8.3.6. Rest of Europe
   8.4. APAC
      8.4.1. Australia
      8.4.2. China
      8.4.3. India
      8.4.4. Japan
      8.4.5. Rest of APAC
   8.5. ROW
      8.5.1. Middle East & Africa
      8.5.2. South America
9. Market Entropy
   9.1. New Product Launches
   9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles
   10.1. Abbott Laboratories
   10.2. Becton, Dickinson and Company
   10.3. Bio/Data Corporation
   10.4. Axis-Shield Diagnostics Ltd.
   10.5. Helena Company Inc.
   10.6. Sysmex Corporation
   10.7. Thermo Fisher Scientific Inc.
   10.8. Corgenix Medical Corporation
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports